Novel targets in prostate cancer

Expert Opinion on Therapeutic Targets

Volumn 10, Issue 5, 2006, Pages 777-780

  Berthold, Dominik R ^a   Moore, Malcolm J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Androgen receptor; End point determination; Prostatic neoplasm; Sorafinib; Targeted therapy; Vitamin D

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CALCITRIOL; CETUXIMAB; DN 101; DOCETAXEL; ERLOTINIB; GEFITINIB; PLACEBO; PROSTATE SPECIFIC ANTIGEN; PROVENGE; RAF PROTEIN; SORAFENIB; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TRASTUZUMAB; VITAMIN D; VITAMIN D RECEPTOR;

ANTINEOPLASTIC ACTIVITY; BONE SCINTISCANNING; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; HUMAN; NONHUMAN; PROGNOSIS; PROSTATE CANCER; PROSTATE SURGERY; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; RECEPTOR BLOCKING; THROMBOEMBOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; GEORGIA; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 33749241106     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.10.5.777     Document Type: Conference Paper

References (15)

1. DONOVAN MJ, SCHER H, SCARDINO P, KOTSIANTI A, CORDON-CARDO C: Systems pathology for building predictive models: The androgen receptor as a prototype biomarker in prostate cancer progression and targeted therapeutic response assessment. 2006 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. (2006) 24(Suppl. 18):Abstract 4504.
2. LI R, WHEELER T, DAI H et al.: High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am. J. Surg. Pathol. (2004) 28(7):928-934.
3. SCHER HI, SAWYERS CL: Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signalling axis. J. Clin. Oncol. (2005) 23(32):8253-8261.
4. SADI MV, BARRACK ER. Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. Cancer (1993) 71(8):2574-2580.
5. PRINS GS, SKLAREW RJ, PERTSCHUK LP: Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy. J. Urol. (1998) 159(3):641-649.
6. GASTON KE, FORD IO, SINGH S et al.: A novel method for the analysis of the androgen receptor. Curr. Urol. Rep. (2002) 3(1):67-74.
7. VENNER PM, RYAN C, PETRYLAK DP et al.: Reduced thromboembolic events with DN-101 (high-dose calcitriol) treatment of androgen-independent prostate cancer: Hypothesis for a new class of anticoagulants. 2006 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. (2006) 24(Suppl. 18):Abstract 4505.
8. BEER TM, RYAN CW, VENNER PM et al.: Interim results from ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel versus placebo plus docetaxel in androgen-independent prostate cancer (AIPC). 2005 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. (2005) 23(Suppl. 16):Abstract 4516.
9. THOMAS MK, LLOYD-JONES DM, THADHANI RI et al.: Hypovitaminosis D in medical in-patients. N. Engl. J. Med. (1998) 338(12):777-783.
10. KATO S, TAKEYAMA K, KITANAKA S et al.: In vivo function of VDR in gene expression-VDR knockout mice. J. Steroid Biochem. Mol. Biol. (1999) 69(1-6):247-251.
11. AIHARA K, AZUMA H, AKAIKE M et al.: Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J. Biol. Chem. (2004) 279(34):35798-35802.
12. DAHUT WL, SCRIPTURE CD, POSADAS EM et al.: Bony metastatic disease responses to sorafenib (BAY 43-9006) independent of PSA in patients with metastatic androgen independent prostate cancer. 2006 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. (2006) 24(Suppl. 18).Abstract 4506.
13. BAKIN RE, GIOELI D, SIKES RA, BISSONETTE EA, WEBER MJ: Constitutive activation of the Ras/mitogen-activated protein kinase signalling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res. (2003) 63(8):1981-1989.
14. DAHUT WL, GULLEY JL, ARLEN PM et al.: Randomized Phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J. Clin. Oncol. (2004) 22(13):2532-2539.
15. ARMSTRONG AJ, CARDUCCI MA: New drugs in prostate cancer. Curr. Opin. Urol. (2006) 16(3):138-145.